Study of SON-1010 (IL12-FHAB) in Healthy Adults - Trial NCT05408572
Access comprehensive clinical trial information for NCT05408572 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sonnet BioTherapeutics and is currently Recruiting. The study focuses on Healthy Adult. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sonnet BioTherapeutics
Timeline & Enrollment
Phase 1
Jul 27, 2022
Dec 30, 2022
Primary Outcome
To evaluate the safety and tolerability of SON-1010 as a single-ascending dose (SAD) in healthy adults.
Summary
SB102 is a randomized, double-blind, single center, placebo-controlled study in healthy
 adults starting with sentinel participants at each dose level to carefully assess the safety,
 tolerability, PK, and PD of SON-1010.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05408572
Non-Device Trial